Comparative Pharmacology
Head-to-head clinical analysis: NITRO BID versus NITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO BID versus NITROL.
NITRO-BID vs NITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
None Documented
None Documented
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator